Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...
So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with *** lower risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback